Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

Diabetes costs: 1 in every 10 healthcare dollars

The economic cost of diagnosed diabetes totaled $245 billion in 2012, according to an analysis by the American Diabetes Association. The 41 percent increase from 2007 costs was fueled by a spike in diabetes prevalence.

FDA investigates pancreatic toxicity with diabetes drug class

The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and precancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on exam of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.

ACC: On-pump CABG is not more beneficial in highest risk patients

SAN FRANCISCO—Off-pump surgery in high-risk patients is associated with a lower incidence of serious complications, and is a safer way of direct revascularization in these patients, according to the late-breaking PRAGUE-6 trial, presented March 11 at the American College of Cardiology (ACC) scientific session.

ACC: Older patients don't benefit from on-pump CABG

SAN FRANCISCO—In patients 75 years of age or older, there was no significant difference between on-pump and off-pump CABG in the composite outcome of death, stroke, MI, repeat revascularization or new renal-replacement therapy within 30 days and within one year after surgery, according to the late-breaking GOPCABE trial, presented March 11 at the American College of Cardiology (ACC) scientific session.

ACC slides: Cardiac troponin can measure risk in ischemic heart disease

SAN FRANCISCO—Serial measurements of cardiac troponin using an investigational high-sensitivity assay enhanced risk stratification for cardiovascular disease and heart failure in patients with stable ischemic heart disease, according to an analysis of the PROVE IT-TIMI 22 study, presented March 9 at the American College of Cardiology’s (ACC) scientific session.

FDA: Awareness, not excessive bleeds, hounds Pradaxa

An FDA analysis using its Mini-Sentinel program puts the anticoagulant dabigatran once again on equal footing with warfarin for bleeding risks. The report, published online March 14 as a perspectives article in the New England Journal of Medicine, attributes the high number of postmarket cases of bleeding to “stimulated reporting.” 

Cordis wraps up Flexible Stenting deal

Cordis has completed its acquisition of Flexible Stenting Solutions, a developer of flexible peripheral arterial, venous and biliary stents.

FDA warns of arrhythmia risk with Zithromax

The FDA issued a warning that azithromycin (Zithromax, Pfizer) can cause potentially fatal arrhythmias.

Displaying 8281 - 8288 of 10761

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.